Back to How We Help Clients

Generics and Biosimilars

Helping companies capture opportunities across the value chain for generics, branded generics, established products and biosimilars, and forging connections among industry stakeholders.

What we do

We work with all participants in the generics industry, including independent companies, the generics divisions of large corporations, active pharmaceutical ingredient (API) manufacturers, specialty pharmaceutical companies, private equity, wholesalers, pharmacy benefit managers (PBMs), and payors. Our work has covered a wide range of topics, including strategy, operations, marketing, R&D, organization, due diligence, and post-merger management. We offer benchmarking and diagnostic tools in R&D, manufacturing and cost structures.

Forging connections

In keeping with the goals of the practice, we emphasize industry outreach. We convene the Generics CEO Summit for industry leaders, providing an important forum for knowledge sharing and networking. In the past, key discussion topics included capital markets perspectives, biosimilars, quality, and complexity management.

We also attend and present at key external industry conferences, including those organized by the European Generic Medicines Association and the Convention on Pharmaceutical Ingredients (CPhI).

Featured experts

Simon Goeller

Partner, Munich

Sathya Prathipati

Senior Partner, Mumbai

Featured Insights


Three imperatives for R&D in biosimilars

– The biosimilars market is poised to grow over the next decade. Here’s how companies can accelerate time to market, reduce R&D costs, and improve productivity.

Understanding the opportunity in Japan’s biosimilar market

– Despite a sluggish start, Japan’s biosimilar market looks set for accelerated growth. The country’s patient co-pay dynamic, financial incentives, and commercial model will be keys to success.

Five things to know about biosimilars right now

– In the biosimilars market, companies face declining prices and rising competition. What themes will shape the industry in coming months, and how can players set themselves apart?